Fortress Biotech, Inc. (FBIOP)

NASDAQ: FBIOP · Real-Time Price · USD · Preferred Stock
7.78
+0.80 (11.46%)
At close: May 30, 2025, 4:00 PM
7.76
-0.02 (-0.26%)
After-hours: May 30, 2025, 4:08 PM EDT
11.46%
Market Cap 55.82M
Revenue (ttm) 57.78M
Net Income (ttm) -50.75M
Shares Out 29.55M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend $0.20 (2.51%)
Ex-Dividend Date Jun 14, 2024
Volume 27,171
Open 6.94
Previous Close 6.98
Day's Range 6.94 - 7.96
52-Week Range 4.72 - 17.45
Beta 1.86
Analysts n/a
Price Target n/a
Earnings Date May 13, 2025

About FBIOP

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 101
Stock Exchange NASDAQ
Ticker Symbol FBIOP
Full Company Profile

Financial Performance

In 2024, Fortress Biotech's revenue was $57.68 million, a decrease of -31.76% compared to the previous year's $84.51 million. Losses were -$55.89 million, -18.61% less than in 2023.

News

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cos...

Other symbols: FBIO
1 day ago - GlobeNewsWire

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoi...

Other symbols: FBIO
16 days ago - GlobeNewsWire

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...

Other symbols: FBIO
24 days ago - GlobeNewsWire

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, ...

Other symbols: FBIO
2 months ago - Seeking Alpha

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic ...

Other symbols: FBIO
2 months ago - GlobeNewsWire

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors

Other symbols: FBIO
4 months ago - GlobeNewsWire

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones C...

Other symbols: FBIO
5 months ago - GlobeNewsWire

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally adv...

Other symbols: FBIO
7 months ago - GlobeNewsWire

Fortress Biotech to Participate in October 2024 Investor Conferences

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term val...

Other symbols: FBIO
8 months ago - GlobeNewsWire

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance ...

Other symbols: FBIO
9 months ago - GlobeNewsWire

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term val...

Other symbols: FBIO
9 months ago - GlobeNewsWire

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults

Other symbols: FBIO
10 months ago - GlobeNewsWire

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a four...

Other symbols: FBIO
11 months ago - GlobeNewsWire

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-te...

Other symbols: FBIO
11 months ago - GlobeNewsWire

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

Fortress Biotech, Inc. (NASDAQ:FBIO) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President and Chief Executive...

Other symbols: FBIO
2 years ago - Seeking Alpha

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

Journey Medical Corporation (NASDAQ:FBIO) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Pa...

Other symbols: FBIO
3 years ago - Seeking Alpha

Plenty Of Further Upside In Fortress Biotech

Fortress Biotech continues to make strides since bottoming out in December.

Other symbols: FBIO
6 years ago - Seeking Alpha